ProFuse Technology

**Product and the concrete problem it solves.** ProFuse Technology addresses two bottlenecks that look separate on a market map but share the same biological constraint: producing mature, functional skeletal muscle outside an animal. In cultivated meat, the company supplies enabling inputs intended to make muscle-cell proliferation, differentiation, fusion, and maturation faster and more productive. The commercial problem is not merely growing more cells; it is reaching useful tissue quality and yield without allowing growth media, process time, and bioreactor complexity to make the finished product uneconomic. Cultivated-meat producers must also move beyond thin or poorly organized cell masses toward tissue with more convincing structure, texture, and nutritional characteristics. In life sciences, the corresponding problem is that immature or oversimplified laboratory models can produce misleading drug-discovery results. ProFuse now applies its muscle-cultivation know-how to a high-throughput platform for muscle atrophy, muscle disease, regeneration, and metabolic-health research. The company sells or develops cell lines and media products for cultivated-meat customers while pursuing licensing and collaboration opportunities around drug and dietary-supplement candidates. This is an enabling-technology business rather than a branded meat producer or a conventional therapeutics company, so its upside depends on becoming embedded in other organizations' workflows.

**Core technology and how it actually works.** The platform originated in roughly six years of Weizmann Institute research led by Prof. Eldad Tzahor, Dr. Ori Avinoam, and Dr. Tamar Eigler-Hirsh. Public company and European project materials describe a biochemical-signaling approach that accelerates the differentiation and fusion of muscle cells, rather than treating media as a generic nutrient mixture. ProFuse has described the activation of a signaling pathway, protected at the time as patent-pending, that helps myoblasts mature into organized muscle tissue. Its cultivated-meat product work includes PROFUSE-S1, a differentiation-media supplement, and PROFUSE-B8, a bovine muscle-cell line; the current website also describes a human-muscle discovery platform. In the company's three-dimensional models, mature muscle fibers can form between pillars or on scaffolds, creating a geometry in which contraction and force can be measured instead of relying only on cell counts or fluorescent markers. For drug discovery, the platform adds engineered human cell lines with reporters associated with disease states, enabling time-resolved observation of muscle atrophy or disease progression. ProFuse also describes software that images hundreds of thousands of cells and rapidly quantifies differentiation efficiency, fiber size, maturity, and related measurements. These details point to a combined wet-lab and computational assay system. They remain company-reported capabilities: public sources do not establish independent head-to-head performance against every competing media formulation, nor do they disclose full pathway chemistry, formulation composition, cell-line genomic stability, or the complete patent family.

**Market, customers, and go-to-market.** ProFuse's initial market is business-to-business cultivated-meat production, where a supplier can sell a small but critical input across many producers instead of funding its own consumer manufacturing footprint. The company has said it works with cultivated-meat producers and has developed formulations for different two-dimensional and three-dimensional applications. Its 2022 financing announcement said proceeds would support collaboration with producers, laboratory expansion, research hiring, and work toward regulatory approval. The current strategic extension is a second B2B motion into pharmaceutical, biotechnology, and nutraceutical research. ProFuse's high-throughput screening platform is designed to test thousands of compounds for muscle-preservation or regeneration effects, with a potential path to license promising candidates to drug companies for later validation. The GLP-1 weight-loss market gives that motion a timely wedge because rapid weight loss can be accompanied by loss of lean mass, although ProFuse has not publicly demonstrated a clinical product or a clinical outcome. The practical go-to-market sequence is therefore likely to be reagent, cell-line, assay, and collaboration sales first, followed by licensing or partnered development if the assays produce reproducible hits. The public record names strategic ecosystem participants such as Tnuva, Tempo, OurCrowd, Fresh Start, and cultivated-food investors, but it does not name current paying customers, disclose recurring revenue, or establish the size and terms of customer collaborations. Those omissions matter because adoption in both cultivated meat and drug discovery requires reproducibility, technical support, regulatory documentation, and customer-specific validation.

**Traction, funding, and third-party validation.** ProFuse has accumulated a meaningful validation trail for a small deep-tech company, although the evidence is still weighted toward grants, investors, and technical programs rather than disclosed commercial scale. It was founded in 2021 through the Israel Innovation Authority-backed Fresh Start FoodTech incubator, and public coverage records an initial approximately $1.25 million seed investment involving Fresh Start and the Innovation Authority. In September 2022, the company announced a $2.5 million seed round led by Green Circle, with participation from existing shareholders OurCrowd, Tnuva, and Tempo and new participants including Siddhi Capital and Kayma; the announcement put cumulative funding at $3.75 million at that point. In 2024, the European Innovation Council awarded the PROFUSE project a €2.432 million contribution under the EIC Transition program, with the European Commission describing the project as developing a bovine myoblast line and muscle-growth technology for cultivated meat. Startup Nation Finder reports a further $1.5 million seed financing in July 2026 from Green Circle Foodtech Ventures, Tempo Beverages, and Siddhi Capital, while AgFunderNews describes the same financing as supporting the expansion into muscle-health discovery. ProFuse also reports winning first place in the 2021 Israel FoodTech Startup Competition and receiving follow-on Innovation Authority support. The Weizmann Institute's case study connects the company to named academic leads and explains the underlying research. Taken together, these are credible ecosystem and technology-validation signals. They do not prove regulatory approval, commercial repeatability, clinical efficacy, or production-scale cultivated-meat economics, and the company has not publicly disclosed valuation, revenue, gross margins, or a named customer list.

**Founders and team background.** The founding group fits the unusual biology-to-commercialization requirements of the platform. Guy Nevo Michrowski is the co-founder and CEO; ProFuse's current materials describe more than two decades of company-building, management, business development, fundraising, and commercialization experience across technology-driven sectors, along with a B.Sc. in International Business Management from the University of Surrey and executive education at Northwestern's Kellogg School of Management. Dr. Tamar Eigler-Hirsh is co-founder and CTO and brings the central muscle-biology expertise: the company identifies her work with skeletal-muscle development, regenerative biology, molecular signaling, and the regulation of progenitor-cell differentiation and fusion. Public food-tech materials also identify Prof. Eldad Tzahor and Dr. Ori Avinoam as scientific founders or research leaders. Tzahor is a Weizmann developmental-biology and cardiac-regeneration researcher whose laboratory studied mechanisms relevant to skeletal and cardiac muscle formation; Avinoam's profile emphasizes cell-to-cell fusion and imaging of muscle structure and function. ProFuse's current website says the R&D team is strengthened by Tzahor and Prof. Shulamit Levenberg of the Technion, while drug-discovery materials identify additional scientific-advisory expertise. This combination gives the company unusually direct access to the originating science and a business leader who can translate it into products. The counterpoint is organizational depth: public sources do not provide a complete current roster, exact employee count, manufacturing leadership, regulatory leadership, or evidence that the team has repeatedly taken a cell-biotechnology product through large-scale quality systems. A directory signal of 11-50 employees is useful only as a range, not as a verified headcount.

**Competitive dynamics.** ProFuse competes across several layers rather than against one obvious substitute. In cultivated meat, it faces vertically integrated producers such as Upside Foods, Mosa Meat, and Believer Meats, which can develop proprietary media, cell lines, and process recipes internally and may prefer to protect their manufacturing data. It also faces enabling-input specialists such as Multus Biotechnology and other media or growth-factor suppliers, whose products can be tested as alternatives in the same production workflows. In Israel, Tnuva's Ever After Foods represents a strategically connected cultivated-meat platform and can be a partner, customer, or potential internal substitute depending on the relationship. In drug discovery, ProFuse competes with academic muscle-organoid laboratories, contract research organizations, pharmaceutical companies' internal assays, and companies building organ-on-chip or induced-pluripotent-stem-cell models. Its claimed edge is the integration of mature, functional muscle tissue with throughput: a model that can contract, generate force, expose disease-linked reporters, and be quantified at scale is more decision-useful than an immature two-dimensional culture if the biology translates. Yet each advantage is vulnerable. A producer could obtain similar outcomes through media optimization, recombinant growth factors, genetic engineering, or a better cell line; a pharmaceutical buyer may demand blinded external replication, benchmark compounds, assay robustness, and a clear regulatory path; and platform customers may resist dependence on a small supplier. The moat must therefore become a validated dataset, a reproducible formulation and cell-line system, protected intellectual property, and a workflow that customers would rather license than rebuild.

**Defense, security, and resilience dual-use relevance.** ProFuse's strategic relevance is strongest on food and biomedical resilience, not on direct defense procurement. The same core capability can support more productive cultivated-protein manufacturing and more predictive muscle-health research, two civilian functions that matter during supply, climate, disease, and healthcare disruptions. A scalable muscle-production input could contribute to a more diversified protein supply that uses less land and potentially less water than conventional livestock, while a mature human-muscle assay could help screen interventions for sarcopenia, treatment-related muscle loss, rehabilitation, or other conditions that burden health systems. That is a credible resilience pathway because it targets production efficiency and biological-model quality rather than a discretionary consumer feature. There is also a longer-term security adjacency: domestic or allied capacity to manufacture specialized biological inputs and to test countermeasures quickly can reduce dependence on fragile international supply chains. However, no public source reviewed here shows a defense customer, military contract, biodefense program, government deployment, or fielded security application. The technology is not inherently a weapons or intelligence capability, and it should not be presented as one. The dual-use score therefore reflects commercial biology with a plausible food-security and health-resilience contribution, moderated by the absence of government demand, validated nutritional outcomes, and demonstrated production at strategic scale. Regulatory governance, biosafety, data rights, and responsible use of engineered cell lines remain central to any resilience expansion.

**Growth stage, trajectory, and key diligence risks.** ProFuse is best classified as early-stage despite having operated since 2021, accumulated multiple forms of funding, and launched a second application area. Its trajectory runs from academic discovery to cultivated-meat reagents and cell lines, then toward higher-value screening and licensing products for muscle health. The 2024 EIC project had a defined transition window through March 2026, and the 2026 financing signals that the company is still funding platform development and commercialization rather than reporting mature recurring revenue. The upside is attractive if ProFuse can show that its products reduce cost or cycle time in real customer processes and that its human-muscle assays predict outcomes better than incumbent models. The diligence agenda is substantial: (1) reproduce cell-line performance, differentiation, fusion, contraction, and force data across lots and laboratories; (2) verify the full patent posture, freedom to operate, and ownership of Weizmann-derived inventions; (3) separate grant-funded technical milestones from paying-customer traction; (4) test whether cultivated-meat customers can achieve favorable unit economics at bioreactor scale rather than only in 2D or small 3D experiments; (5) evaluate contamination control, media consistency, cold-chain or storage requirements, and quality systems; (6) determine whether GLP-1-related muscle-loss assays lead to licensable programs, validated biomarkers, or merely exploratory screens; and (7) assess funding runway in a capital-intensive sector whose customer budgets and regulatory timelines are uncertain. The company has a coherent scientific foundation and a sensible resilience thesis, but the key value inflection remains independent proof that its biology becomes a repeatable, paid production or discovery advantage.